StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Investment analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report released on Friday. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, Barclays dropped their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Stock Performance

NASDAQ:CLLS opened at $1.67 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $92.83 million, a P/E ratio of -1.28 and a beta of 3.08. The firm has a 50-day moving average price of $1.80 and a two-hundred day moving average price of $1.98. Cellectis has a twelve month low of $1.41 and a twelve month high of $3.38.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same quarter in the prior year, the firm earned ($0.31) earnings per share. As a group, research analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Several hedge funds have recently made changes to their positions in CLLS. Long Focus Capital Management LLC lifted its position in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares during the period. First Affirmative Financial Network acquired a new position in shares of Cellectis during the 3rd quarter valued at about $45,000. Finally, XTX Topco Ltd purchased a new position in shares of Cellectis during the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.